Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer-Reference-Cited by-同舟云学术

Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer

Published:2020-10-31 Issue:12 Volume:111 Page:4442-4452
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci.

Author:

Kagawa Yusuke¹²,Furuta Hiromi¹^ORCID,Uemura Takehiro¹²,Watanabe Naohiro¹,Shimizu Junichi¹,Horio Yoshitsugu¹,Kuroda Hiroaki³,Inaba Yoshitaka⁴,Kodaira Takeshi⁵,Masago Katsuhiro⁶,Fujita Shiro⁶,Niimi Akio²,Hida Toyoaki¹^ORCID

Affiliation:

1. Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya Japan

2. Department of Respiratory Medicine, Allergy and Clinical Immunology Nagoya City University Graduate School of Medicine Sciences Nagoya Japan

3. Department of Thoracic Surgery Aichi Cancer Center Hospital Nagoya Japan

4. Department of Diagnostic and Interventional Radiology Aichi Cancer Center Hospital Nagoya Japan

5. Department of Radiation Oncology Aichi Cancer Center Hospital Nagoya Japan

6. Department of Pathology and Molecular Diagnostics Aichi Cancer Center Hospital Nagoya Japan

Funder

Kyowa Hakko Kirin

Chugai Pharmaceutical

Bristol-Myers Squibb

Taiho Pharmaceutical

Merck Sharp and Dohme

Astellas Pharma Canada

AbbVie

Ono Pharmaceutical

Clovis Oncology

Daiichi Sankyo Company

Pfizer

Novartis Pharma

Takeda Pharmaceutical Company

AstraZeneca

Boehringer Ingelheim

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14605

Reference46 articles.

1. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

2. The blockade of immune checkpoints in cancer immunotherapy

3. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

4. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

5. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy;Clinical Lung Cancer;2024-08

2. A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors;Cancer Immunology, Immunotherapy;2024-07-02

3. Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence;European Respiratory Review;2024-04-30

4. Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies;Current Oncology Reports;2024-01

5. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression;Clinical Lung Cancer;2024-01